ES2796235T3 - Derivados de naftiridina como antagonistas de la integrina alfa V beta 6 para el tratamiento de enfermedades fibróticas - Google Patents
Derivados de naftiridina como antagonistas de la integrina alfa V beta 6 para el tratamiento de enfermedades fibróticas Download PDFInfo
- Publication number
- ES2796235T3 ES2796235T3 ES15767479T ES15767479T ES2796235T3 ES 2796235 T3 ES2796235 T3 ES 2796235T3 ES 15767479 T ES15767479 T ES 15767479T ES 15767479 T ES15767479 T ES 15767479T ES 2796235 T3 ES2796235 T3 ES 2796235T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- ethyl
- acid
- formula
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc1cc(N)cc(*)c1 Chemical compound Cc1cc(N)cc(*)c1 0.000 description 4
- KARUMYWDGQTPFL-UHFFFAOYSA-N Brc1cc(Br)cc(I)c1 Chemical compound Brc1cc(Br)cc(I)c1 KARUMYWDGQTPFL-UHFFFAOYSA-N 0.000 description 1
- OYIIHXSFOFCWJS-NSCUHMNNSA-N CC(/C=C/CC(F)(F)F)=O Chemical compound CC(/C=C/CC(F)(F)F)=O OYIIHXSFOFCWJS-NSCUHMNNSA-N 0.000 description 1
- CZBFLSHTYIRHPM-UHFFFAOYSA-N CC1(C)OB(c2cc(-[n]3nc(C)cc3)cc(N3CCOCC3)c2)OC1(C)C Chemical compound CC1(C)OB(c2cc(-[n]3nc(C)cc3)cc(N3CCOCC3)c2)OC1(C)C CZBFLSHTYIRHPM-UHFFFAOYSA-N 0.000 description 1
- FDMFKTHTSWPJDW-UFUCKMQHSA-N C[N]1(CCOCC1)c1cccc(C(CC(O)=O)CN2C[C@H](CCc3nc(NCCC4)c4cc3)CC2)c1 Chemical compound C[N]1(CCOCC1)c1cccc(C(CC(O)=O)CN2C[C@H](CCc3nc(NCCC4)c4cc3)CC2)c1 FDMFKTHTSWPJDW-UFUCKMQHSA-N 0.000 description 1
- ZAXNYRBQVGSJRU-UHFFFAOYSA-N Cc(cc1)n[n]1-c1cc(Br)cc(Br)c1 Chemical compound Cc(cc1)n[n]1-c1cc(Br)cc(Br)c1 ZAXNYRBQVGSJRU-UHFFFAOYSA-N 0.000 description 1
- SZEGTQISVXEDQY-UHFFFAOYSA-N Cc(cc1)n[n]1-c1cc(Br)cc(N2CCOCC2)c1 Chemical compound Cc(cc1)n[n]1-c1cc(Br)cc(N2CCOCC2)c1 SZEGTQISVXEDQY-UHFFFAOYSA-N 0.000 description 1
- VBMMJNFNKQXFRN-OOQGMUEZSA-N Cc(cc1)n[n]1-c1cc(N2CCOCC2)cc(C(CC(O)=O)CN(CC2)C[C@@]22C(Cc3nc(NCCC4)c4cc3)C2)c1 Chemical compound Cc(cc1)n[n]1-c1cc(N2CCOCC2)cc(C(CC(O)=O)CN(CC2)C[C@@]22C(Cc3nc(NCCC4)c4cc3)C2)c1 VBMMJNFNKQXFRN-OOQGMUEZSA-N 0.000 description 1
- YVHXDXZEAGPPPM-PPUHSXQSSA-N OC(CC(CN1C[C@H](CCc2ccc(CCCN3)c3n2)CC1)c1cc(N2CCOCC2)cc(I)c1)=O Chemical compound OC(CC(CN1C[C@H](CCc2ccc(CCCN3)c3n2)CC1)c1cc(N2CCOCC2)cc(I)c1)=O YVHXDXZEAGPPPM-PPUHSXQSSA-N 0.000 description 1
- QEIWHNLFOUGMMS-FPSALIRRSA-N OC(CC(CN1C[C@H](CCc2nc(NCCC3)c3cc2)CC1)c1cc(-c2ccn[nH]2)cc(N2CCOCC2)c1)=O Chemical compound OC(CC(CN1C[C@H](CCc2nc(NCCC3)c3cc2)CC1)c1cc(-c2ccn[nH]2)cc(N2CCOCC2)c1)=O QEIWHNLFOUGMMS-FPSALIRRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417018.7A GB201417018D0 (en) | 2014-09-26 | 2014-09-26 | Novel compounds |
| PCT/EP2015/071798 WO2016046241A1 (en) | 2014-09-26 | 2015-09-22 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2796235T3 true ES2796235T3 (es) | 2020-11-26 |
Family
ID=51901174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15767479T Active ES2796235T3 (es) | 2014-09-26 | 2015-09-22 | Derivados de naftiridina como antagonistas de la integrina alfa V beta 6 para el tratamiento de enfermedades fibróticas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10004724B2 (OSRAM) |
| EP (1) | EP3197895B1 (OSRAM) |
| JP (1) | JP6672276B2 (OSRAM) |
| KR (1) | KR20170054413A (OSRAM) |
| CN (1) | CN107074850A (OSRAM) |
| AU (1) | AU2015320874A1 (OSRAM) |
| BR (1) | BR112017006240A2 (OSRAM) |
| CA (1) | CA2962319A1 (OSRAM) |
| ES (1) | ES2796235T3 (OSRAM) |
| GB (1) | GB201417018D0 (OSRAM) |
| RU (1) | RU2017114352A (OSRAM) |
| WO (1) | WO2016046241A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| CA3042693A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Pyrrole amides as .alpha.v integrin inhibitors |
| HRP20220990T1 (hr) | 2016-11-08 | 2022-11-11 | Bristol-Myers Squibb Company | 3-supstituirane propionske kiseline kao inhibitori alfa v integrina |
| KR102506324B1 (ko) | 2016-11-08 | 2023-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물 |
| WO2018089357A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS |
| JP7128811B2 (ja) | 2016-11-08 | 2022-08-31 | ブリストル－マイヤーズ スクイブ カンパニー | アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | (ALPHA-V) (BETA-6) INHIBITORS INTEGRIN |
| EP3760202A1 (en) | 2017-02-28 | 2021-01-06 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2019094319A1 (en) | 2017-11-07 | 2019-05-16 | Bristol-Myers Squibb Company | Pyrrolopyrazine derivatives as alpha v integrin inhibitors |
| PL3844162T3 (pl) | 2018-08-29 | 2025-06-09 | Morphic Therapeutic, Inc. | Inhibitory integryny alfa v beta 6 |
| EP3617206A1 (en) | 2018-08-29 | 2020-03-04 | Morphic Therapeutic, Inc. | Integrin inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002508323A (ja) * | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| GEP20032921B (en) | 1997-12-17 | 2003-03-25 | Merck & Co Inc | Integrin Receptor Antagonists Pharmaceutical Compositions Containing the Same and Methods for Treatment |
| IL146378A0 (en) | 1999-06-02 | 2002-07-25 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| WO2000078317A1 (en) | 1999-06-23 | 2000-12-28 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2003510360A (ja) * | 1999-10-04 | 2003-03-18 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| HUP0203246A3 (en) | 1999-11-08 | 2003-12-29 | Merck & Co Inc | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| US6933304B2 (en) * | 2000-06-15 | 2005-08-23 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| ATE353219T1 (de) | 2000-07-26 | 2007-02-15 | Merck & Co Inc | Alpha v integrin-rezeptor-antagonisten |
| AU2001290772A1 (en) | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
| EP1349548A4 (en) | 2001-01-03 | 2004-06-02 | Merck & Co Inc | METHOD AND COMPOSITIONS FOR TREATING PERIODONTOSIS |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| WO2004058254A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| US7705018B2 (en) | 2007-03-23 | 2010-04-27 | Amgen Inc. | Substituted quinolines and their uses in treatment of inflammatory and related conditions |
| EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016134223A2 (en) | 2015-02-19 | 2016-08-25 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファｖベータ１インテグリン阻害剤及び使用方法 |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2014
- 2014-09-26 GB GBGB1417018.7A patent/GB201417018D0/en not_active Ceased
-
2015
- 2015-09-22 WO PCT/EP2015/071798 patent/WO2016046241A1/en not_active Ceased
- 2015-09-22 BR BR112017006240A patent/BR112017006240A2/pt not_active Application Discontinuation
- 2015-09-22 RU RU2017114352A patent/RU2017114352A/ru unknown
- 2015-09-22 JP JP2017516386A patent/JP6672276B2/ja not_active Expired - Fee Related
- 2015-09-22 KR KR1020177007735A patent/KR20170054413A/ko not_active Withdrawn
- 2015-09-22 AU AU2015320874A patent/AU2015320874A1/en not_active Abandoned
- 2015-09-22 CA CA2962319A patent/CA2962319A1/en active Pending
- 2015-09-22 ES ES15767479T patent/ES2796235T3/es active Active
- 2015-09-22 EP EP15767479.7A patent/EP3197895B1/en active Active
- 2015-09-22 US US15/514,414 patent/US10004724B2/en not_active Expired - Fee Related
- 2015-09-22 CN CN201580052202.3A patent/CN107074850A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016046241A1 (en) | 2016-03-31 |
| AU2015320874A1 (en) | 2017-03-09 |
| CN107074850A (zh) | 2017-08-18 |
| RU2017114352A (ru) | 2018-10-26 |
| KR20170054413A (ko) | 2017-05-17 |
| BR112017006240A2 (pt) | 2017-12-12 |
| GB201417018D0 (en) | 2014-11-12 |
| US10004724B2 (en) | 2018-06-26 |
| JP6672276B2 (ja) | 2020-03-25 |
| CA2962319A1 (en) | 2016-03-31 |
| US20170290818A1 (en) | 2017-10-12 |
| EP3197895A1 (en) | 2017-08-02 |
| JP2017528506A (ja) | 2017-09-28 |
| EP3197895B1 (en) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2796235T3 (es) | Derivados de naftiridina como antagonistas de la integrina alfa V beta 6 para el tratamiento de enfermedades fibróticas | |
| US10513517B2 (en) | Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | |
| ES2814000T3 (es) | Naftiridinas como antagonistas de integrinas | |
| ES2704525T3 (es) | Derivados de naftiridina como antagonistas de integrina AlfaVBeta6 para el tratamiento de, por ejemplo, enfermedades fibróticas | |
| US10342783B2 (en) | Compounds αvβ6 integrin antagonists | |
| ES2665597T3 (es) | Derivados de naftiridina úiles como antagonistas de la v 6 integrina | |
| AU2017232285A1 (en) | Citrate salt of the compound (S)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthydrin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl) butanoic acid |